These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19050916)

  • 21. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
    Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M
    Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus disease in adolescents: management and prevention.
    Widdice LE
    Adolesc Med State Art Rev; 2012 Apr; 23(1):192-206, xii-xiii. PubMed ID: 22764563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recurrent respiratory papillomatosis: indication for HPV vaccination?].
    Pawlita M; Gissmann L
    Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S100-2. PubMed ID: 19353471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HPV vaccination in head and neck HPV-related pathologies.
    Wierzbicka M; Józefiak A; Jackowska J; Szydłowski J; Goździcka-Józefiak A
    Otolaryngol Pol; 2014; 68(4):157-73. PubMed ID: 24981297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Human papillomavirus vaccines: a new challenge for pediatricians].
    Martinón-Torres F; Bernaola Iturbe E; Giménez Sánchez F; Baca Cots M; De Juan Martín F; Díez Domingo J; Garcés Sánchez M; Gómez Campderá JA; Picazo JJ; Pineda Solas V
    An Pediatr (Barc); 2006 Nov; 65(5):461-9. PubMed ID: 17184607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human papillomavirus (HPV) infection, cervical cancer and vaccination against HPV: a Nordic perspective.
    Kjaer SK
    Acta Obstet Gynecol Scand; 2007; 86(11):1286-9. PubMed ID: 17963055
    [No Abstract]   [Full Text] [Related]  

  • 27. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia.
    Pathirana D; Hillemanns P; Petry KU; Becker N; Brockmeyer NH; Erdmann R; Gissmann L; Grundhewer H; Ikenberg H; Kaufmann AM; Klusmann J; Kopp I; Pfister H; Rzany B; Schneede P; Schneider A; Smola S; Winter-Koch N; Wutzler P; Gross G
    Vaccine; 2009 Jul; 27(34):4551-9. PubMed ID: 19524337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human papillomavirus vaccines and adolescents.
    Kahn JA; Bernstein DI
    Curr Opin Obstet Gynecol; 2005 Oct; 17(5):476-82. PubMed ID: 16141761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An overview on the implementation of HPV vaccination in Europe.
    Bonanni P; Levi M; Latham NB; Bechini A; Tiscione E; Lai P; Panatto D; Gasparini R; Boccalini S
    Hum Vaccin; 2011; 7 Suppl():128-35. PubMed ID: 21245659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions.
    Gay J; Johnson N; Kavuru V; Phillips M
    Skin Therapy Lett; 2021 Mar; 26(2):6-8. PubMed ID: 33769773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papilloma virus and cervical preinvasive disease.
    Peltecu G; Bari M; Lancu G; Popa F
    J Med Life; 2009; 2(4):373-7. PubMed ID: 20108750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and natural history of genital human papillomavirus infection.
    Weaver BA
    J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S2-8. PubMed ID: 16729554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE; Vuocolo S
    Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
    Villa LL
    Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Human papilloma virus and cervical cancer].
    Berumen-Campos J
    Gac Med Mex; 2006; 142 Suppl 2():51-9. PubMed ID: 19031679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevention of cervical cancer (II): prophylactic HPV vaccination, current knowledge, practical procedures and new issues].
    Monsonego J
    Presse Med; 2007 Apr; 36(4 Pt 2):640-66. PubMed ID: 17350792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.